Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

PWRM, a development stage company, engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimer?s disease, and Parkinson?s disease.

More about PWRM at: http://www.Power3Medical.com

Make sure you have PWRM on your watch list, be ready for any possible pop!

*******************************

FuelCell Energy, Inc. (Nasdaq:FCEL) a leading manufacturer of high efficiency ultra-clean power plants using renewable and other fuels for commercial, industrial, government, and utility customers announced today that the underwriters of the Company’s public offering of 24.0 million shares of common stock have closed on their over-allotment option to purchase an additional 3.6 million shares of FuelCell Energy common stock and have concluded the offering.

The additional aggregate net proceeds to FuelCell Energy from the over-allotment option totaled approximately $4.2 million after deducting underwriting discounts, fees and expenses. FuelCell Energy intends to use the net proceeds from this offering for product development, project financing, expansion of manufacturing capacity, and general corporate purposes. Lazard Capital Markets LLC acted as the sole book-running manager and Canaccord Genuity Inc. was co-manager for the offering.

More about FCEL at: http://www.deltapetro.com

Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

******************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.read more Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).